As of 30 Sep 2025, 45 institutional investors reported holding $503,553,600 in principal (par value) of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $1,164,850 | $12,987,466 | +$12,153,448 | 9462.9% | 2 |
| 2025 Q3 | $503,553,600 | $706,927,628 | -$1,700,309 | 140.31% | 45 |
| 2025 Q2 | $562,171,600 | $702,674,387 | +$36,427,687 | 124.62% | 45 |
| 2025 Q1 | $574,937,600 | $656,979,517 | +$27,474,461 | 114.27% | 44 |
| 2024 Q4 | $562,886,600 | $590,898,964 | -$57,359,295 | 104.83% | 43 |
| 2024 Q3 | $580,126,900 | $598,911,091 | +$11,943,787 | 103.04% | 42 |
| 2024 Q2 | $560,212,900 | $566,449,836 | -$1,604,582 | 101.01% | 40 |
| 2024 Q1 | $560,289,110 | $603,151,800 | -$105,996,884 | 107.6% | 40 |
| 2023 Q4 | $23,000,000 | $27,841,500 | +$7,263,000 | 121.05% | 1 |
| 2023 Q3 | $527,312,610 | $516,889,796 | +$21,523,566 | 96.13% | 40 |
| 2023 Q2 | $509,098,285 | $408,093,278 | -$33,061,778 | 78.44% | 35 |
| 2023 Q1 | $537,457,499 | $417,146,853 | +$6,942,248 | 74.1% | 36 |
| 2022 Q4 | $532,905,810 | $243,639,855 | +$73,238 | 45.0% | 31 |
| 2022 Q3 | $391,920,480 | $235,383,560 | -$522,455 | 58.88% | 32 |
| 2022 Q2 | $403,586,425 | $223,528,262 | -$83,798,874 | 54.45% | 33 |
| 2022 Q1 | $547,874,444 | $329,728,428 | -$9,335,577 | 58.89% | 35 |
| 2021 Q4 | $523,548,048 | $391,837,974 | -$23,307,900 | 73.22% | 39 |
| 2021 Q3 | $532,866,518 | $746,196,000 | -$33,834,644 | 138.19% | 42 |
| 2021 Q2 | $570,125,000 | $939,036,160 | +$82,169,228 | 164.12% | 38 |
| 2021 Q1 | $519,084,931 | $858,521,718 | +$842,352,735 | 165.39% | 35 |